Market Overview

Recap: Strongbridge Biopharma Q1 Earnings


Shares of Strongbridge Biopharma (NASDAQ:SBBP) were flat in pre-market trading after the company reported Q1 results.

Quarterly Results

Earnings per share increased 24.00% year over year to ($0.19), which beat the estimate of ($0.22).

Revenue of $6,674,000 rose by 53.67% from the same period last year, which beat the estimate of $5,940,000.

Looking Ahead

Earnings guidance hasn't been issued by the company for now.

Strongbridge Biopharma hasn't issued any revenue guidance for the time being.

Details Of The Call

Date: May 06, 2020

Webcast URL:

Recent Stock Performance

52-week high: $3.67

52-week low: $1.43

Price action over last quarter: Up 4.56%

Company Profile

Strongbridge Biopharma PLC is a biopharmaceutical company which focuses on the development, in-licensing, acquisition, and commercialization of various complementary products and product candidates that target rare diseases. The product portfolio of the group includes COR-003(levoketoconazole) and COR-005 (veldoreotide). COR-003 is a cortisol inhibitor which is used for the treatment of endogenous cushing's syndrome and COR-005 a novel somatostatin analog, which is used for the treatment of acromegaly. In addition, it is also developing BP-2002 (gene modified probiotic) which will be used for the treatment of Diabetes. Geographically, business activity of the firm is primarily functioned through the United States.


Related Articles (SBBP)

View Comments and Join the Discussion!

Posted-In: Earnings News